Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Aerovate Therapeutics Inc

Healthcare US AVTE

NoneUSD
0.00(0%)

Last update at 2025-05-28T13:00:52.115467Z

Day Range

--
LowHigh

52 Week Range

1.2532.41
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap77.77M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-89.95700M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.99

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -51.48600M -22.96000M -9.61100M -3.33000M
Minority interest - - - -
Net income -51.51100M -22.96300M -9.03900M -3.33000M
Selling general administrative 14.62M 8.04M 0.95M 0.22M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 0.07M 0.01M 0.00100M 0.00000M
Ebit -53.23700M -23.02200M -8.88900M -3.33100M
Ebitda -53.16900M -23.00700M -9.53500M -3.33000M
Depreciation and amortization 0.07M 0.01M -0.64600M 0.00100M
Non operating income net other - - - -
Operating income -53.23700M -23.02200M -8.88900M -3.33100M
Other operating expenses 53.24M 23.02M 8.89M 3.33M
Interest expense 1.75M 0.07M 0.07M 0.00000M
Tax provision 0.03M 0.00300M - -
Interest income 1.83M - - -
Net interest income 1.83M 0.07M -0.07500M 0.00000M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.03M 0.00300M -0.57200M -0.00100M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 53.24M 23.02M 8.89M 3.33M
Cost of revenue - - - -
Total other income expense net 1.75M 0.06M -0.72200M 0.00100M
Discontinued operations - - - -
Net income from continuing ops -51.51100M -22.96300M -9.61100M -3.33000M
Net income applicable to common shares - -22.98500M -9.76400M -3.33000M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 127.42M 135.30M 175.36M 4.71M 3.51M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.79M 0.29M 0.24M 0.10M -
Total liab 17.96M 8.56M 2.94M 18.06M 7.16M
Total stockholder equity 109.46M 126.74M 172.42M -13.34400M -3.64300M
Deferred long term liab - - - - -
Other current liab 14.82M 4.82M 0.14M 1.16M 0.12M
Common stock 0.00300M 0.00200M 0.00200M - -
Capital stock 0.00300M 0.00200M 0.00200M 0.00000M 0.00000M
Retained earnings -163.42400M -87.90300M -36.39200M -13.40700M -3.64300M
Other liab - 0.07M 0.01M - -
Good will - - - - -
Other assets - 2.56M 0.30M - -
Cash 23.49M 22.40M 54.20M 4.57M 3.51M
Cash and equivalents - - - - -
Total current liabilities 17.64M 7.78M 2.55M 1.77M 0.66M
Current deferred revenue - - 1.01M - -
Net debt -22.81600M -21.30700M -53.62300M -4.57300M -1.01400M
Short term debt 0.42M 0.39M 0.19M - -
Short long term debt - - - - -
Short long term debt total 0.68M 1.09M 0.57M - 2.50M
Other stockholder equity 272.64M 215.11M 33.50M 0.06M -
Property plant equipment - - 0.73M 0.04M -
Total current assets 124.23M 131.50M 174.33M 4.68M 3.51M
Long term investments - - - - -
Net tangible assets - - 172.42M -13.34400M -3.64300M
Short term investments 98.95M 106.82M 113.18M - -
Net receivables - - - - -
Long term debt - - - - 2.50M
Inventory - - - - -
Accounts payable 2.40M 2.58M 1.21M 0.62M 0.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.24M -0.46600M -0.05900M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.28M 2.56M 0.30M - -
Deferred long term asset charges - - - - -
Non current assets total 3.19M 3.81M 1.03M 0.04M 0.00000M
Capital lease obligations 0.68M 1.09M 0.57M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 6.93M -113.43400M -113.25300M -113.25300M
Change to liabilities 0.00000M 0.61M 0.04M 0.44M
Total cashflows from investing activities - -113.43400M -113.43400M -113.43400M
Net borrowings - - 2.50M 2.50M
Total cash from financing activities 0.40M 190.46M 8.92M 2.50M
Change to operating activities - -7.11900M 0.94M 0.11M
Net income -51.51100M -22.96300M -9.61100M -3.33000M
Change in cash -31.80000M 49.62M 1.06M -0.28100M
Begin period cash flow 54.20M 4.57M 3.51M 3.79M
End period cash flow 22.40M 54.20M 4.57M 3.51M
Total cash from operating activities -39.12200M -27.39900M -7.85900M -2.78100M
Issuance of capital stock 0.00000M 190.46M 6.41M 0.00000M
Depreciation 0.07M 0.01M 0.00100M 0.00100M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - - - -
Other cashflows from financing activities 0.25M 63.51M 8.92M 2.50M
Change to netincome 4.57M 2.06M 0.78M 0.78M
Capital expenditures 0.20M 0.18M 0.18M 0.18M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 7.75M -6.51000M 0.97M 0.55M
Stock based compensation 5.48M 2.04M 0.06M 0.00000M
Other non cash items -0.91000M 0.02M 0.72M -
Free cash flow -39.31700M -27.58000M -7.85900M -2.78100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
AVTE
Aerovate Therapeutics Inc		 - -% - - - - 0.96 -9.3264
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Aerovate Therapeutics Inc

930 Winter Street, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. Timothy P. Noyes M.B.A. CEO & Director 1962
Dr. Benjamin T. Dake Ph.D. Founder, Pres, COO & Sec. 1976
Mr. George A. Eldridge CFO & Treasurer 1963
Mr. Hunter Gillies M.D. Chief Medical Officer 1966
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S Chief Scientific Officer 1960
Mr. Timothy J. Pigot Sr. VP of Commercial NA
Ms. Donna Dea Head of Regulatory Affairs NA
Dr. Marinus Verwijs Ph.D. Sr. VP of CMC 1976
Ms. Susan Fischer Sr. VP of Devel. Operations NA
Mr. Stephen Yu Sr. VP of Quality NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.